TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00519532
Drug: Rotigotine
Normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h
Study: NCT02984475
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00005037
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005037
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide capsule once a day for 42 days every 10 weeks.
Study: NCT00069121
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m\^2 intravenous (IV) infusion over two hours on Day 1 of each 3-week cycle.
Study: NCT00069121
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by one of two regimens, as specified in the arm description.
Study: NCT02354001
Drug: Raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120mg daily- 1 capsule for 12 week trial
Study: NCT01115712
Drug: Comparator: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 30 mg once daily
Study: NCT02427581
Drug: Poly ICLC
Normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00055198
Drug: daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02551848
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT01426386
Drug: FE 999049
Normalized name: Fe
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01426386
Drug: Gonal - F
Normalized name: Gonal F
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01457339
Drug: SPD489 (Lisdexamfetamine dimesylate)
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SPD489 administered orally in ascending doses (50mg, 70mg, 100mg, 150mg, 200mg, 250mg). Each of these doses will be administered once daily for 5 days. Total number of days dosed is 30 days.
Study: NCT02660658
Drug: Intrathecal dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance
Study: NCT02730247
Drug: ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
Study: NCT02730247
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.
Study: NCT00950417
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00565422
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/day
Study: NCT00097266
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, oral, 15-30 mg, once daily, 12 weeks.
Study: NCT00097266
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule, oral, 5-15 mg, once daily, 12 weeks.
Study: NCT01096667
Drug: Placebo to Ertuglilflozin 1 or 5 mg
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days
Study: NCT01096667
Drug: Ertugliflozin 1 mg
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertugliflozin tablet 1 mg once daily for 28 days
Study: NCT01096667
Drug: Ertugliflozin 5 mg
Normalized name: ertugliflozin 5 MG
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertugliflozin tablet 5 mg once daily for 28 days
Study: NCT01096667
Drug: Ertugliflozin 25 mg
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertugliflozin tablet 25 mg once daily for 28 days
Study: NCT01096667
Drug: HCTZ 12.5mg
Normalized name: HCTZ 12.5MG/LOSARTAN 50MG TAB
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days
Study: NCT00542984
Drug: teriparatide 20 micrograms/day subcutaneous
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00542984
Drug: salmon calcitonin 100 IU/day subcutaneous
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02522377
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inter venous injections
Study: NCT02522377
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: inter venous injections
Study: NCT04771715
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
Study: NCT04771715
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
Study: NCT04771715
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
Study: NCT04771715
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
Study: NCT04771715
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
Study: NCT04771715
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
Study: NCT04771715
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
Study: NCT00001737
Drug: Cyclosporin A Implant
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02429505
Drug: Miltefosine
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: miltefosine: target 2.5 mg/kg/day for 28 days
Study: NCT02453841
Drug: Oxymetazoline
Normalized name: Oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01073189
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to the Diuretic Control group will receive intravenous furosemide as an active control
Study: NCT00191529
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00495846
Drug: Octreotide-LAR, Lanreotide Autogel
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide-LAR intramuscular, dose of 30 mg every 28 days to increase up to 60 mg; lanreotide autogel 120 mg deep subcutaneous every 28 days for 3 months then uptitrated according with the protocol.
Study: NCT03373591
Drug: Liposomal Bupivacaine TAP block
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
Study: NCT02232789
Drug: Mephedrone
Normalized name: Mephedrone
DrugBank: Mephedrone (DB13108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose mephedrone
Study: NCT02232789
Drug: 3,4-methylenedioxymethamphetamine
Normalized name: 3,4-Methylenedioxymethamphetamine
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose MDMA
Study: NCT03373591
Drug: Bupivacaine TAP block
Normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
Study: NCT00072189
Drug: 7-hydroxystaurosporine
Normalized name: 7-Hydroxystaurosporine
DrugBank: 7-Hydroxystaurosporine (DB01933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00003937
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003937
Drug: dexrazoxane hydrochloride
Normalized name: Dexrazoxane Hydrochloride
DrugBank: Dexrazoxane (DB00380)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003937
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003937
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00144300
Drug: Mirapex
Normalized name: Mirapex
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard marketed product dispensed according to manufacturer's guidelines
Study: NCT00144300
Drug: Requip
Normalized name: Requip
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard marketed product dispensed according to manufacturer's guidelines
Study: NCT02007837
Drug: Combined aspirin and multinutrient supplement
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.
Study: NCT01933672
Drug: PF-04937319 once-daily
Normalized name: PF-04937319
DrugBank: PF-04937319 (DB15009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, 300 mg once-daily with breakfast, 14-days
Study: NCT01933672
Drug: PF-04937319 split-dose
Normalized name: PF-04937319
DrugBank: PF-04937319 (DB15009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days
Study: NCT01933672
Drug: Sitagliptin once-daily
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: tablets, 100 mg once-daily with breakfast, 14-days
Study: NCT00123201
Drug: Dronabinol MDI
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04125745
Drug: CXA-10
Normalized name: CXA-10
DrugBank: CXA-10 (DB15026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive oral CXA-10 at the dose of 300 mg once daily for 12 weeks
Study: NCT02426086
Drug: Imetelstat 4.7 mg/kg
DrugBank: Imetelstat (DB14909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received imetelstat 4.7 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle. Study drug was administered intravenously until disease progression, unacceptable toxicity, or study end.
Study: NCT02426086
Drug: Imetelstat 9.4 mg/kg
DrugBank: Imetelstat (DB14909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received imetelstat 9.4 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or study end.
Study: NCT00524303
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4mg/kg IV loading dose followed by 2mg/kg IV weekly
Study: NCT00524303
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80mg/m2 IV weekly for 4 (21 day) cycles
Study: NCT00524303
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3
Study: NCT03478683
Drug: budesonide/formoterol
Normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
Study: NCT03478683
Drug: albuterol/salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
Study: NCT03478683
Drug: Placebo to match budesonide/formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will be administered two inhalations of matching placebo twice daily via MDI
Study: NCT03478683
Drug: tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
Study: NCT03478683
Drug: placebo to match tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
Study: NCT03828292
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin will be administered as an intravenous infusion.
Study: NCT04345848
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two different doses of anticoagulation
Study: NCT03828292
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib solution for injection will be administered subcutaneously.
Study: NCT03828292
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone tablets will be administered orally.
Study: NCT03828292
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide capsules will be administered orally.
Study: NCT00041899
Drug: COB-2914
Normalized name: CORN COB
DrugBank: Corn (DB10572)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02510599
Drug: solithromycin
Normalized name: solithromycin
DrugBank: Solithromycin (DB09308)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00887042
Drug: Fludarabine, Busulfan, Thymoglobulin
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 \& -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, \& -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, \& -6)
Study: NCT01690832
Drug: fenoldopam infusion
DrugBank: Fenoldopam (DB00800)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure
Study: NCT04761185
Drug: Raltitrexed
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed in HIPEC
Study: NCT02986451
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle
Study: NCT02986451
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle.
Study: NCT04135781
Drug: nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab paclitaxel （120mg/m2；iv；d1，8）
Study: NCT04135781
Drug: Tegafur
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: S-1 （\<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）
Study: NCT04135781
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin（130mg/m2 , iv, d1）
Study: NCT03117933
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet, 100mg and 150mg
Study: NCT03117933
Drug: Cediranib
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet 15mg and 20mg
Study: NCT03117933
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV)
Study: NCT00231478
Drug: granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 micrograms intravenously (iv) 15 min prior to end of surgery
Study: NCT00231478
Drug: granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 micrograms intravenously (iv) 15 min prior to end of surgery
Study: NCT00853905
Drug: Triesence
Normalized name: Triesence
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At end of standard glaucoma surgery and the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure, 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound.
Study: NCT00152373
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02330991
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00686751
Drug: paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.
Study: NCT02757495
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose caudal epidural injection will be done using 25 G needle. patients of Group BD will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%,
Study: NCT04002687
Drug: ATV-PG 1000-400 mg + AQ 612 mg
Normalized name: PG
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).
Study: NCT03294304
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be given at a fixed dose of 360 mg IV over 30 minutes on Day 8 every 21 days for 4 cycles.
Study: NCT03294304
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be given at 70 mg/m2 IV over 30 minutes on Day 1 every 21 days, and based on treating physician's discretion, split-dose cisplatin can be given at 35 mg/m2 IV Day 1 and Day 8 every 21 days for 4 cycles.
Study: NCT03294304
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1, 8, and every 21 days for 4 cycles.
Study: NCT00101088
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT00101088
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00727857
Drug: Pioglitazone and metformin
Normalized name: Pioglitazone and Metformin Hydrochloride Tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pioglitazone 15 mg /metformin 850 mg combination, tablets, orally, twice daily for up to 24 weeks.
Study: NCT00727857
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 15 mg, tablets, orally, twice daily for up to 24 weeks.
Study: NCT02426866
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00393458
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
Study: NCT00393458
Drug: Formoterol
Normalized name: Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
Study: NCT00393458
Drug: Placebo to indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).